Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

Severe, life-threatening adverse reactions to capecitabine sometimes occur in the treatment of solid tumors. Screening for dihydropyrimidine dehydrogenase (DPYD) deficiency is encouraged before start of treatment, but the genetic variants that are commonly analyzed often fail to explain toxicities s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: García-González, Xandra, López-Tarruella, Sara, García, María Isabel, González-Haba, Eva, Blanco, Carolina, Salvador-Martin, Sara, Jerez, Yolanda, Thomas, Fabienne, Jarama, María, Sáez, María Sanjurjo, Martín, Miguel, López-Fernández, Luis Andrés
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190816/
https://ncbi.nlm.nih.gov/pubmed/30349384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S174470
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars